GlassScriptPhysician profile
Robin E Witham-Curry
NPI 1700833423
$1,908.76
in general payments reported to CMS, 2019-2025
22 companies · $273 in 2025
The $273 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $579 · 2023: $557 · 2024: $500 · 2025: $273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,330.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,329.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $258.91 | 2022-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Axsome Therapeutics, INC. | $237.27 | 2022-2025 | Auvelity, Sunosi |
| Lundbeck LLC | $230.07 | 2022-2025 | Rexulti |
| Corium, LLC | $195.70 | 2022-2024 | Azstarys |
| Alkermes, INC. | $174.80 | 2022-2024 | Aristada, Lybalvi, Vivitrol |
| Novo Nordisk INC | $148.65 | 2022-2023 | Wegovy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $143.41 | 2022-2024 | Caplyta |
| Lilly USA, LLC | $88.88 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $74.94 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.61 | 2023-2025 | Jardiance |
| Indivior INC. | $43.84 | 2022 | |
| Ironshore Pharmaceuticals INC. | $38.57 | 2022 | |
| Tris Pharma INC | $33.16 | 2022-2024 | Dyanavel Xr |
| E.R. Squibb & Sons, L.L.C. | $32.81 | 2023-2024 | Eliquis |
| Pfizer INC. | $32.55 | 2023-2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $20.84 | 2023 | Ingrezza |
| Collegium Pharmaceutical, INC. | $19.95 | 2025 | Jornay Pm |
| Janssen Pharmaceuticals, INC | $19.80 | 2023 | Invega Sustenna, Invega Trinza |
| Bayer Healthcare Pharmaceuticals INC. | $16.54 | 2022 | |
| Medtronic, INC. | $16.37 | 2023 | Intellis Adaptivestim |
| Jazz Pharmaceuticals INC. | $15.56 | 2024 | |
| Boston Scientific Corporation | $13.53 | 2025 | Wavewriter Alpha Prime 16 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Witham-Curry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.